Public-registry trials using GRT-C903 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Gritstone bio, Inc. | Non-Small Cell Lung Cancer | PHASE1 / PHASE2 | 12 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →